CoChat
Sign Up
Cited by 146

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo

Anisimov, Vladimir N., Egormin, Peter A., Piskunova, Tatiana S., Popovich, Irina G., Tyndyk, Margarita L., Yurova, Maria N., Zabezhinski, Mark A., Anikin, Ivan V., Karkach, Arseniy S., Romanyukha, Alexey A.·2010·Cell Cycle
DOI 10.4161/cc.9.1.10407
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4161/cc.9.1.10407

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 8 references

Research works printed but not linked: 54

  1. Evans JM, Donnelly LA, Emslie-Smith, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330:1304-5.
  2. Currie CJ, Poole CD, Gale EAM. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52:1766-77.
  3. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, et al. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu trans- genic mice. Exp Gerontol 2005; 40:685-93.
  4. Bojkova B, Orendas P, Garajlova M, Kassayova M, Kutna V, Ahlersova E, et al. Metformin in chemically- induced mammary carcinogenesis in rats. Neoplasma 2009; 56:269-74.
  5. Baturin DA, Alimova IN, Anisimov VN, Popovich IG, Zabezhinski MA, Provinciali M, et al. The effect of light regimen and melatonin on the development of spontaneous mammary tumors in HER-2/neu trans- genic mice is related to a downregulation of HER-2/ neu gene expression. Neuroendocr Lett 2001; 22:441- 7.
  6. Anisimov VN, Alimova IN, Baturin DA, Popovich IG, Zabezhinski MA, Manton KG, et al. The effect of melatonin treatment regimen on mammary adenocarci- noma development in HER-2/neu transgenic mice. Int J Cancer 2003; 103:300-5.
  7. Sánchez-Barceló EJ, Cos S, Fernández R, Mediavilla MD. Melatonin and mammary cancer: a short review. Endocr Relat Cancer 2003; 10:153-9.
  8. Anisimov VN, Popovich IG, Zabezhinski MA, Anisimov SV, Vesnushkin GM, Vinogradova IA. Melatonin as antioxidant, geroprotector and anticar- cinogen. Biochim Biophys Acta 2006; 1757:573-89.
  9. Dilman VM, Anisimov VN. Effect of treatment with phenformin, dyphenylhydantoin or L-DOPA on life span and tumor incidence in C3H/Sn mice. Gerontology 1980; 26:241-5.
  10. Vinnitski VB, Iakimenko VA. Effect of phenformin, L-DOPA, and parachlorophenylalanine on the immu- nological reactivity and chemical carcinogenesis in BALB/c mice. Vopr Onkol 1981; 27:45-50.
  11. Colman RJ, Anderson RM, Johnson SC, Kastman EK, Kosmatka KJ, Beasley TM, et al. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 2009; 325:201-4.
  12. Mabuchi S, Altomare DA, Connolly DC, Klein-Szanto A, Litwin S, Hoelzle MK, et al. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res 2007; 67:2408-13.
  13. Granville CA, Warfel N, Tsurutani J, Hollander MC, Robertson M, Fox SD, et al. Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity and phenotypic progression of tobacco carcinogen-induced murine lung tumors. Clin Cancer Res 2007; 13:2281-9.
  14. Namba R, Young LJ, Abbey CK, Kim L, Damonte P, Borowsky AD, et al. Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ. Clin Cancer Res 2006; 12:2613-21.
  15. Robinson J, Lai C, Martin A, Nye E, Tomlinson I, Silver A. Oral rapamycin reduces tumour burden and vascularization in Lkb1(+/-) mice. J Pathol 2009; 219:35-40.
  16. Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res 2007; 42:28-42.
  17. Kimball SR, Abbas A, Jefferson LS. Melatonin represses oxidative stress-induced activation of the MAP kinase and mTOR signaling pathways in H4IIE hepatoma cells through inhibition of RAS. J Pineal Res 2008; 44:379-86.
  18. Anisimov VN, Alimova IN, Baturin DA, Popovich IG, Zabezhinski MA, Rosenfeld SV, et al. Dose-dependent effect of melatonin on life span and spontaneous tumor incidence in female SHR mice. Exp Gerontol 2003; 38:449-61.
  19. Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, Merino MJ, et al. The mammary pathol- ogy of genetically engineered mice: the consensus report and recommendations from the Annapolis meet- ing. Oncogene 2000; 19:968-88.
  20. Fletcher R. Practical Methods of Optimization (2 nd ed.,). New York: Wiley 1987.
  21. Davison AC, Hinkley DV. Bootstrap Methods and Their Application, Cambridge: Cambridge University Press 1997.
  22. Cox D. Regression models and life-tables (with dis- cussion). J R Stat Soc Ser B (Methodological) 1972; 34:187-220.
  23. Ben Sahra I, Laurent K, Lounat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008; 27:3576-86.
  24. Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, Thor AD. Metformin induces unique bio- logical and molecular responses in triple negative breast cancer cells. Cell Cycle 2009; 8:2031-40.
  25. Caraci F, Chisari M, Frasca G, Chiechio S, Salomone S, Pinto A, et al. Effects of phenformin on the prolifera- tion of human tumor cell lines. Life Sci 2003; 74:643- 50.
  26. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007; 67:10804-12.
  27. Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, Thor AD. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009; 15; 8:909-15.
  28. Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res 2008; 1:369-75.
  29. Gotlieb WH, Saunet J, Beauchamp M-C, Gu J, Lau S, Pollak MN, Bruchim I. In vitro metformin anti- neoplastic activity in epithelial ovarian cancer. Gynecol Oncol 2008; 110:246-50.
  30. Vucicevic L, Misirkik M, Janjetovic K, Harhaji- Trajkoviic L, Prica M, Stevanovic D, et al. AMP- activated proteinkinase-dependent and -independent mechanisms underlying in vitro antiglioma action of compound C. Biochem Pharmacol 2009; 77:1684-93.
  31. Strack T. Metformin: a review. Drugs Today 2008; 44:303-14.
  32. Anisimov VN. Role of the growth hormone-insulin- like growth factor-1-insulin system signaling in aging and longevity: evolutional aspect. Ross Fiziol Zh Im I M Sechenova 2008; 94:1092-109.
  33. Muntoni S. Metformin and fatty acids. Diabetes Care 1999; 22:179-80.
  34. Gargiulo P, Caccese D, Pignatelli P, Brufani C, De Vito F, Marino R, et al. Metformin decreases platelet super- oxide anion production in diabetic patients. Diabetes Metab Res Rev 2002; 18:156-9.
  35. Blagosklonny MV. Validation of anti-aging drugs by treating age-related diseases. Aging 2009; 1:281-8.
  36. Blagosklonny MV, Campisi J. Cancer and aging: more puzzles, more promises? Cell Cycle 2008; 7:2615-8.
  37. Gargiulo P, Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124:471-84.
  38. Huang X, Wullschleger S, Shpiro N, McGuire VA, Sakaoto K, Woods YL, et al. Important role of the LKB1-AMPK pathway in suppressing tumorgenesis in PTEN-deficient mice. Biochem J 2008; 412:211-21.
  39. Anisimov VN. Effect of buformin and diphenylhy- dantoin on life span, estrus function and spontaneous tumor incidence in female rats. Vopr Onkol 1980; 26:42-8.
  40. Anisimov VN, Semenchenko AV, Yashin AI. Insulin and longevity: antidiabetic biguanides as geroprotec- tors. Biogerontology 2003; 4:297-307.
  41. Anisimov VN. Effect of phenformin on life span, estrus function and spontaneous tumor incidence in rats. Farmakol Toksikol 1982; 45:127.
  42. Dilman VM, Berstein LM, Zabezhinski MA, Alexandrov VA, Pliss GB. Inhibition of DMBA-induced carcino- genesis by phenformin in the mammary gland of rats. Arch Geschwulstforsch 1978; 48:1-8.
  43. Anisimov VN, Belous NM, Vasilyeva IA, Dilman VM. Inhibitory effect of phenformin on the development of mammary tumors induced by N-nitrosomethylurea in rats. Exp Onkol 1980; 2:40-3.
  44. Anisimov VN, Ostroumova MN, Dilman VM. Inhibition of blastomogenic effect of 7,12- dimethylbenz(a)anthracene in female rats by buformin, dipheninhydantoin, polypeptide pineal extract and L-DOPA. Bull Exp Biol Med 1980; 89:723-5.
  45. Alexandrov VA, Anisimov VN, Belous NM, Vasilyeva IA, Mazon VB. The inhibition of the transplacental blastomogenic effect of nitrosomethylurea by postnatal administration of buformin to rats. Carcinogenesis 1980; 1:975-8.
  46. Bespalov VG, Alexandrov VA. Influence of anticarcino- genic agents on the transplacental carcinogenic effect of N-nitroso-N-ethylurea. Bull Exp Biol Med 1985; 100:73-6.
  47. Dilman VM, Sofronov BN, Anisimov VN, Nazarov PG, Lvovich EG. Phenformin elimination of the immunodepression caused by 1,2-dimethylhydrazine in rats. Vopr Onkol 1977; 23:50-4.
  48. Anisimov VN, Pozharisski KM, Dilman VM. Effect of phenformin on the blastomogenic action of 1,2- dimethylhydrazine in rats. Vopr Onkol 1980; 26:54-8.
  49. Anisimov VN, Belous NM, Prokudina EA. Inhibition by phenformin of the radiation carcinogenesis in female rats. Exp Onkol 1982; 4:26-9.
  50. Schneider MB, Matsuzaki H, Harorah J, et al. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 2001; 120:163-70.
  51. Dilman VM, Anisimov VN. Potentiation of antitumor effect of cyclophosphamide and hydrazine sulfate by treatment with the antidiabetic agent, 1-phenylethyl- biguanide (phenformin). Cancer Lett 1979; 7:357-61.
  52. Shikhman AR, Lebedev KA, Dilman VM. Suppressive effect of phenformin (phenethyl-biguanide) on the growth of Ehrlich carcinoma. Vopr Onkol 1981; 2:67-9.
  53. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007; 67:6745-52.
  54. Phoenix KN, Vumbaca F, Claffey KP. Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERα negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat 2009; 113:101- 11.

Cited by

Sorted by citations

See all 146

Metadata

Authors
Anisimov, V. N., Egormin, P. A., Piskunova, T. S., Popovich, I. G., Tyndyk, M. L., Yurova, M. N., Zabezhinski, M. A., Anikin, I. V., Karkach, A. S., & Romanyukha, A. A.
Venue
Cell Cycle
Publisher
Informa UK Limited
Published
2010-01
Volume
9
Issue
1
Pages
188-197
ISSN
  • 1538-4101
  • 1551-4005
DOI
10.4161/cc.9.1.10407
Cited by
146
References
8
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review